Company Performance - AbbVie closed at $226.22, down 1.27% from the previous session, underperforming the S&P 500's gain of 0.4% [1] - Over the past month, AbbVie shares increased by 5.95%, outperforming the Medical sector's gain of 1.8% and the S&P 500's gain of 1.02% [1] Upcoming Earnings - AbbVie is set to release its earnings report on October 31, 2025, with an expected EPS of $2.72, reflecting a 9.33% decline year-over-year [2] - The Zacks Consensus Estimate projects net sales of $15.59 billion, which is a 7.81% increase from the same quarter last year [2] Fiscal Year Estimates - For the entire fiscal year, earnings are estimated at $11.54 per share and revenue at $60.68 billion, indicating increases of 14.03% and 7.72% respectively from the previous year [3] - Recent changes in analyst estimates for AbbVie may indicate shifting business trends, with positive revisions suggesting optimism about the company's outlook [3] Zacks Rank and Stock Performance - The Zacks Rank system, which ranges from 1 (Strong Buy) to 5 (Strong Sell), currently ranks AbbVie at 3 (Hold) [5] - Over the past month, the Zacks Consensus EPS estimate has decreased by 9.65% [5] Valuation Metrics - AbbVie has a Forward P/E ratio of 19.86, which is higher than the industry average of 14.43 [6] - The company has a PEG ratio of 1.4, compared to the Large Cap Pharmaceuticals industry's average PEG ratio of 1.6 [6] Industry Context - The Large Cap Pharmaceuticals industry, part of the Medical sector, holds a Zacks Industry Rank of 97, placing it in the top 40% of over 250 industries [7] - Research indicates that industries in the top 50% outperform those in the bottom half by a factor of 2 to 1 [7]

Core Insights - Dividend growth is a reliable edge, with companies that regularly raise dividends often outperforming the S&P 500 due to stronger, growing earnings [1] Group 1: Companies Highlighted - Costco operates membership warehouse stores with a recent quarterly dividend increase from $1.16 to $1.30 per share, resulting in a current yield of 0.56% [4] - Costco has about 914 warehouses and maintains a member renewal rate around 90%, supporting steady fee income and traffic [5] - Costco's payout ratio is 27%, allowing for faster dividend growth as earnings rise, despite a high P/E ratio of 50.3 [6] Group 2: AbbVie Overview - AbbVie focuses on immunology, oncology, and neuroscience, paying a quarterly dividend of $1.64 per share, yielding 2.85% annually [7] - AbbVie's payout ratio is 304%, which is high but typical in the pharmaceutical industry due to significant spending on research and one-time items [7] - Dividend growth in companies like AbbVie tends to reflect earnings growth, indicating durable cash flow and disciplined capital allocation [8]

Core Insights - AbbVie (ABBV) continues to lead in the immunology sector, driven by strong sales of its blockbuster drugs, Skyrizi and Rinvoq, which have helped the company achieve top-line growth despite the loss of exclusivity for Humira over two years ago [1][8] - The upcoming third-quarter results, scheduled for release on October 31, will be closely monitored by investors to assess the continuation of this growth momentum [1] Immunology Performance - Skyrizi and Rinvoq are approved for major indications previously covered by Humira, including a new indication for atopic dermatitis, and are performing well, particularly in the inflammatory bowel disease (IBD) segment, which includes ulcerative colitis (UC) and Crohn's disease (CD) [2] - Strong growth in the immunology market, market share gains, and new indications, such as Skyrizi's launch in UC and Rinvoq's approval for giant cell arteritis (GCA), are expected to enhance Q3 performance, with estimated sales of $4.54 billion for Skyrizi and $2.16 billion for Rinvoq [3] Expansion into Other Therapeutic Areas - AbbVie is diversifying its portfolio beyond immunology, with significant growth in neuroscience driven by the uptake of migraine treatments, Ubrelvy and Qulipta [4] - The oncology segment has also expanded, moving beyond hematologic cancers into solid tumors, supported by new drugs like Elahere and Emrelis [4] Competitive Landscape - The immunology market is highly competitive, with Johnson & Johnson (JNJ) as a key player, marketing Stelara and Tremfya for multiple indications, including UC and CD [5] - Eli Lilly (LLY) is also increasing its presence in immunology with the recent FDA approval of Omvoh for UC, marking its first immunology drug for IBD in the U.S. [6] Financial Performance and Valuation - AbbVie shares have outperformed the industry year-to-date, reflecting strong demand for Skyrizi and Rinvoq, which have restored top-line growth following Humira's patent loss [7][8] - AbbVie is currently trading at a premium valuation, with a price/earnings (P/E) ratio of 16.72, above the industry average of 15.70 and its five-year mean of 13.16 [10] - The bottom-line estimate per share for 2025 has slightly decreased from $12.02 to $11.93, while estimates for 2026 have increased from $14.32 to $14.42 over the past month [11]

Core Insights - AbbVie’s injection of E-type botulinum toxin (TrenibotE) has received acceptance for market application, classified as Category 1 [1] - The indication for TrenibotE is projected to be for moderate to severe glabellar lines based on clinical trial progress [1] Group 1 - TrenibotE is a first-in-class E-type botulinum neurotoxin, with the first market application submitted to the FDA in April 2025 [3] - The application is supported by clinical research data from over 2,100 patients treated with TrenibotE, including two pivotal Phase III studies (M21-500 and M21-508) and one Phase III open-label safety study (M21-509) [3] - All primary and secondary endpoints of the Phase III studies have been met, with effects observed as early as 8 hours post-administration and lasting for 2-3 weeks [3] Group 2 - Adverse events associated with TrenibotE treatment were similar to those of the placebo, regardless of whether it was a single treatment or up to three consecutive treatments [3]

Group 1 - Company Abby has shown aggressive growth this year, up approximately 30%, and offers a good dividend yield with attractive valuation [1] - Amazon has experienced a slight increase recently but has lagged behind other AI-related stocks, despite strong performance in AWS, indicating potential for future growth [2] - Six Street, a private credit lender, is highlighted as a high-quality investment opportunity with a yield of 9.5%, despite recent market trends affecting private equity stocks negatively [3] Group 2 - Data Dog is anticipated to break out to new highs, suggesting strong future performance potential, as discussed in a previous conversation among industry experts [4]

Core Viewpoint - AbbVie announced the FDA approval of a supplemental new drug application (sNDA) for RINVOQ (upadacitinib), allowing its use in adults with moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD) after one approved systemic therapy when TNF blockers are clinically inadvisable [1][2]. Group 1: Product Information - RINVOQ is now indicated for patients with moderately to severely active UC or CD who have had an inadequate response or intolerance to one or more TNF blockers, and can be prescribed after one approved systemic therapy if TNF blockers are not suitable [2]. - RINVOQ is a JAK inhibitor developed by AbbVie, which is being studied for various immune-mediated inflammatory diseases [9][10]. Group 2: Patient Support and Access - AbbVie offers a patient support program and a co-pay card that may reduce out-of-pocket costs to $0 per month for eligible, commercially insured patients [5]. - The company has a Patient Assistance Program, myAbbVieAssist, for uninsured patients or those unable to afford their medication [5]. Group 3: Company Commitment - AbbVie is dedicated to addressing the needs of patients with inflammatory bowel disease (IBD), aiming to alleviate the physical, emotional, and economic burdens associated with UC and CD [2][8]. - The company is committed to innovative research in gastroenterology, focusing on developing treatments for IBD [32].

Core Insights - AbbVie is set to present new data from its antibody-drug conjugate (ADC) portfolio at the 2025 ESMO Congress, focusing on treatments for difficult-to-treat cancers [1][2] Group 1: Temab-A Developments - Temab-A, an investigational c-Met directed ADC, will have three oral presentations showcasing its clinical activity across various solid tumors [2][3] - In a Phase 1 study, Temab-A demonstrated an objective response rate (ORR) of 46% in patients with advanced MET-amplified solid tumors, with higher responses in non-small cell lung cancer (NSCLC) at 69% and gastroesophageal adenocarcinoma (GEA) at 71% [4] - In combination with bevacizumab for advanced colorectal cancer (CRC), Temab-A achieved an ORR of 26.7% compared to 0% with the current standard of care [4] Group 2: ABBV-706 Insights - ABBV-706, a SEZ6-directed ADC, is being analyzed in a Phase 1 study for relapsed/refractory small cell lung cancer (R/R SCLC), with findings suggesting it may replace platinum-based standard of care [5][6] - The treatment resulted in rapid clearance of circulating tumor DNA (ctDNA), indicating its potential as an early response marker in SCLC [5] - A Phase 2 study is ongoing to assess ABBV-706 in combination with atezolizumab as a first-line treatment for SCLC [6] Group 3: ESMO Congress Presentations - Key presentations at the ESMO 2025 Congress will include results from studies on Temab-A and ABBV-706, highlighting their efficacy and potential in treating various cancers [7][15]

Piper Sandler将艾伯维的目标价从231美元上调至284美元，维持"增持"评级。(格隆汇) ...

Core Insights - The article discusses the concept of Dividend Kings, which are companies that have increased their dividends for over 50 consecutive years, highlighting their resilience and consistent growth in dividends [4] Group 1: Dividend Kings Overview - Dividend Kings are companies that have a long history of increasing dividends, making them attractive for long-term income investors [4][7] - The article emphasizes the importance of selecting companies with a positive consensus from analysts, focusing on stability and growth potential [1][2] Group 2: Company Profiles AbbVie Inc. (ABBV) - AbbVie reported a revenue increase of approximately 3.7% to $56.33 billion, but net income declined by 12% to around $4.28 billion, resulting in a basic EPS of $2.40 for 2024 [12] - The forward dividend payout is $6.56, with a yield of 6.56% and a payout ratio of 59.92% [13] - Analysts rate AbbVie as a Moderate Buy with a score of 4.21 out of 5, indicating a potential upside of 21.38% from its current price [14][15] Johnson & Johnson (JNJ) - Johnson & Johnson's revenue rose roughly 4.3% to $88.82 billion, but net income declined nearly 60% due to a discontinued operation, resulting in a basic EPS of $5.84 [18] - The forward dividend payout is $5.20, yielding 5.2% with a payout ratio of 49.88% [20] - Analysts rate JNJ as a Moderate Buy with a score of 4.04 out of 5, suggesting an upside potential of 11.5% [21][22] Lowe's Companies (LOW) - Lowe's revenue declined 3% to $83.67 billion, with net income down approximately 10% to $6.96 billion, leading to a basic EPS of $12.25 [26] - The forward dividend is $4.80, yielding 4.80% with a payout ratio of 38.46% [28] - Analysts rate Lowe's as a Moderate Buy with a score of 4.21 out of 5, with a potential upside of 38.5% [29][30] Abbott Laboratories (ABT) - Abbott's revenue increased by 4.5% to $41.95 billion, and net income surged 134% to $13.4 billion, resulting in a basic EPS of $7.67 [33] - The company has declared 399 consecutive quarterly dividends and has increased its payout for 51 consecutive years, with a current yield of 1.77% [34] - Analysts rate Abbott as a Strong Buy with a score of 4.43, indicating a potential upside of 19.2% [36] Coca-Cola Company (KO) - Coca-Cola's revenue for FY'24 was just over $47 billion, up 2.8%, while net income declined slightly by 0.8%, with a basic EPS of $2.47 [38] - The forward dividend is $2.04 annually, yielding just over 3%, with a 21.25% increase in dividends over the past five years [40] - Analysts rate Coca-Cola as a Strong Buy with a score of 4.76, suggesting an upside potential of 28% [40]

North Chicago, Illinois-based AbbVie Inc. (ABBV) focuses on creating medicines and solutions that address complex health issues and enhance people's lives through its core therapeutic areas: immunology, oncology, neuroscience, eye care, aesthetics, and more. With a market cap of $408.5 billion, AbbVie operates as one of the largest biopharmaceutical companies in the world. The pharma giant is gearing up to announce its third-quarter results before the market opens on Friday, Oct. 31. Ahead of the event, a ...